SEPN Septerna Earnings and EPS analysis

Relative Growth: Rel. Growth: 63

Relative Strength: Rel. Strength: 90

Relative Valuation: Rel. Valuation: 7

Relative Profitability: Rel. Profitability: 47

EPS in 2026 (TTM): -$0.81

Last Report Period Date: Mar 31, 2026

As of June this year, based on Septerna's most recent financial report, the company's trailing twelve months EPS is -$0.81. During 2025, SEPN reported a per-share earnings of -$1.1, which shows a rise compared to the EPS of -$7.26 recorded in 2024. Septerna's EPS for the quarterly period ending on Mar 31, 2026 came in at -$0.19.

SEPN earnings history

Historical annual and quarterly earnings per share (EPS) data for Septerna

EPS (TTM)

-$0.81

EPS Growth YoY (Quarterly)

61.2%

EPS (Quarterly)

-$0.19

EPS Growth (Quarterly)

20.8%

The yearly earnings per share during 2025 was -$1.1, a rise of 84.8% compared to -$7.26 recorded in 2024. Over the quarter ending Mar 31, 2026, the earnings per share came in at -$0.19, reflecting a 61.2% increase compared to the same quarter a year earlier. As of March 2026, the TTM EPS is -$0.81. During 2024, the annual earnings per share was -$7.26, representing a decrease of 2,603.4% compared to 2023.

SEPN earnings chart

SEPN EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

61.2%

EPS growth YoY

84.8%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

In the past 12 months, Septerna has recorded an earnings per share growth rate of 61.2% (YoY, quarterly).

SEPN Earnings Waterfall

Breakdown of revenue, profit and net income for Septerna

SEPN Earnings vs Peers

What are the earnings of SEPN compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
REGN Regeneron Pharmaceuticals Inc	14.76	5.3%	2.1%	5.7%
GILD Gilead Sciences Inc	17.41	1,700%	23.2%	132.8%
BIIB Biogen Inc	21.02	-21.2%	-25%	-18.7%
AMGN Amgen Inc	23.87	88.1%	5.6%	2.9%
VRTX Vertex Pharmaceuticals Inc	25.97	843.3%	6%	8.2%
ILMN Illumina Inc	30.44	171.1%	N/A	4.1%
MRNA Moderna Inc	N/A	21.8%	N/A	N/A
NVAX Novavax Inc	N/A	321.1%	N/A	N/A
CRSP CRISPR Therapeutics AG	N/A	-49.1%	N/A	N/A
SEPN Septerna Inc.	N/A	84.8%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.